AAM
NBIX icon

Azzad Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Azzad Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.16M Sell
8,777
-234
-3% -$31K 0.12% 210
2025
Q4 		$1.28M Buy
9,011
+65
+0.7% +$9.42K 0.13% 203
2025
Q3 		$1.26M Buy
+8,946
New +$1.21M 0.12% 214

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Azzad Asset Management's NBIX Position: Q1 2026 in Review

Azzad Asset Management reduced its Neurocrine Biosciences (NBIX) stake by 2.6% in Q1 2026, selling an estimated $31K and leaving 8,777 shares worth $1.16M. The position accounts for 0.12% of the portfolio, ranked #210.

Azzad Asset Management first reported a position in NBIX in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.28M in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Azzad Asset Management held 8,777 shares of Neurocrine Biosciences worth $1.16M as of Q1 2026.
  • Azzad Asset Management sold 234 Neurocrine Biosciences shares in Q1 2026, an estimated $31K.
  • Neurocrine Biosciences made up 0.12% of Azzad Asset Management's portfolio in Q1 2026, its #210 holding.
  • Azzad Asset Management first reported a position in Neurocrine Biosciences in Q3 2025 and has held it in 3 quarters since.
  • Azzad Asset Management's Neurocrine Biosciences position peaked at $1.28M in Q4 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Azzad Asset Management's 13F filing for Q1 2026, filed 30 Apr 2026.